Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Small Cell Lung Carcinoma 4Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Mesothelioma 1Head and Neck Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × rovalpituzumab tesirine × Clear all
NCT03000257 2022-04-14

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Completed
182 enrolled
BreastDermatologicGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03086239 2021-08-03

A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer

AbbVie

Phase 1 Completed
29 enrolled
Thoracic

Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡